ProQR Therapeutics NV said it plans to sell $75 million of its ordinary shares in an underwritten public offering.
The Cambridge, Mass.-based company also granted its underwriters an option to buy up to an additional $11.3 million worth of ordinary shares.
ProQR intends to use the net proceeds from the offering to fund research and development activities as well as for working capital and general corporate purposes.
The company's shares shot up more than 66% on Sept. 5 after the company said its medicine was effective in treating a rare inherited eye disease.
Citigroup, Evercore ISI and RBC Capital Markets are acting as joint book runners for the offering, the company said in a Sept. 5 news release.